<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1312">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05144074</url>
  </required_header>
  <id_info>
    <org_study_id>platelet storage lesion</org_study_id>
    <nct_id>NCT05144074</nct_id>
  </id_info>
  <brief_title>Assessment of Platelet Storage Lesion(PSL)in Platelet Concentrates</brief_title>
  <official_title>CD62P(P-selectin) as a Marker of Assessment of Platelet Storage Lesion(PSL)in Platelet Concentrates</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study to assess platelet activation during 5 days storage of platelet&#xD;
      concentrates prepared by different techinques .&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Platelet transfusion is a lifesaving procedure that is carried out to prevent bleeding or&#xD;
      stop ongoing bleeding in patients with low platelet count or functional platelet disorders.&#xD;
      There are minimum thresholds at which platelets are transfused in these patients, as not all&#xD;
      low levels of platelet warrants a transfusion. Platelet is a scarce resource as processing,&#xD;
      preparing, and transfusing it requires a great deal of precision and effort to maintain a&#xD;
      certain quality. This activity highlights the use of platelet transfusion by the&#xD;
      interprofessional team (1).&#xD;
&#xD;
      Platelets play an integral role in hemostasis by its response to vascular injury. The&#xD;
      relevance of platelet component therapy was better understood in the 1950s and 1960s when&#xD;
      severe and fatal hemorrhagic complications of chemotherapy in leukemia were studied&#xD;
&#xD;
      The collected blood units were randomly assigned to two groups:&#xD;
&#xD;
        1. Non-filtered platelet concentrates (NF-PC group).&#xD;
&#xD;
        2. leukocyte-depleted platelet concentrates (LD-PC group). P-selectin (CD62p) is a type of&#xD;
           glycoprotein stored in the Weibel-Palade bodies of vascular endothelial cells and&#xD;
           platelet α-granules. Activated CD62P is a transmembrane protein expressed on the&#xD;
           platelet surface. During platelet activation, the expression of CD62P on the surface of&#xD;
           the cell membrane is dramatically increased in PCs without leukocyte depletion, due to&#xD;
           the presence of WBCs and cytokines ,and is accompanied by an increase in the expression&#xD;
           level of plasma soluble CD62&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2021</start_date>
  <completion_date type="Anticipated">March 2025</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>assess platelet activation .</measure>
    <time_frame>baseline</time_frame>
    <description>assess platelet activation during 5 days storage of platelet concentrates prepared by different techinques .</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CD62p assessment .</measure>
    <time_frame>baseline</time_frame>
    <description>CD62p assessment of platelet storage lesion(PSL)in platelet concentrates .</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Platelet Storage Lesion(PSL)</condition>
  <arm_group>
    <arm_group_label>Non-filtered platelet concentrates (NF-PC group).</arm_group_label>
    <description>In NF-PC group, 90 whole blood units were collected with Tripple blood bags, Six NF-PCs were pooled together and stored in a horizonal shaker at 20 ± 2C for 5 days .</description>
  </arm_group>
  <arm_group>
    <arm_group_label>leukocyte-depleted platelet concentrates (LD-PC group).</arm_group_label>
    <description>In LD-PC group, another 90 whole blood units were collected using Whole Blood Filter Saving Platelets (WB-SP) bags with an integrated leukoreduction filter</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        All gender fullfilling inclusion criteria are participating in this study ,&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Donors who met criteria of Egyptian National Transfusion services&#xD;
&#xD;
          -  Donors who had not taken any antiplatelet drugs for two weeks prior to donation&#xD;
&#xD;
          -  pre-collection platelet count ≥200×109 /L.&#xD;
&#xD;
          -  Blood grouping.&#xD;
&#xD;
          -  Serological assays for all blood donors (HBsAgs, HCV antibodies, HIV Ag/Ab Syphilis&#xD;
             antibodies) on Architect i 2000 SR or Centaur XPT (chemoluminescence).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Donors who not met criteria of Egyptian National Transfusion services&#xD;
&#xD;
          -  Donors who had taken any antiplatelet drugs for two weeks prior to donation&#xD;
&#xD;
          -  pre-collection platelet count &lt;200×109 /L.&#xD;
&#xD;
          -  Reactive serology&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Merna M. Ayad, resident</last_name>
    <phone>01284539330</phone>
    <email>Mernamamdoh150@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Maha A. Mohamed, professor</last_name>
    <phone>01000004572</phone>
    <email>Atwa_maha@yahoo.com</email>
  </overall_contact_backup>
  <reference>
    <citation>Freireich EJ. Origins of platelet transfusion therapy. Transfus Med Rev. 2011 Jul;25(3):252-6. doi: 10.1016/j.tmrv.2011.01.003. Epub 2011 Mar 2. Review.</citation>
    <PMID>21371858</PMID>
  </reference>
  <reference>
    <citation>Kaushansky K. The molecular mechanisms that control thrombopoiesis. J Clin Invest. 2005 Dec;115(12):3339-47. Review.</citation>
    <PMID>16322778</PMID>
  </reference>
  <reference>
    <citation>Solves Alcaina P. Platelet Transfusion: And Update on Challenges and Outcomes. J Blood Med. 2020 Jan 24;11:19-26. doi: 10.2147/JBM.S234374. eCollection 2020. Review.</citation>
    <PMID>32158298</PMID>
  </reference>
  <reference>
    <citation>Cines DB, Levine LD. Thrombocytopenia in pregnancy. Hematology Am Soc Hematol Educ Program. 2017 Dec 8;2017(1):144-151. doi: 10.1182/asheducation-2017.1.144. Review.</citation>
    <PMID>29222249</PMID>
  </reference>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 21, 2021</study_first_submitted>
  <study_first_submitted_qc>December 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 3, 2021</study_first_posted>
  <last_update_submitted>December 2, 2021</last_update_submitted>
  <last_update_submitted_qc>December 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Merna Mamdoh Ayad Benyamen</investigator_full_name>
    <investigator_title>resident</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

